BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37595822)

  • 1. Clinical course of cervical intraepithelial neoplasia grade 2: a population-based cohort study.
    Lycke KD; Kahlert J; Damgaard RK; Eriksen DO; Bennetsen MH; Gravitt PE; Petersen LK; Hammer A
    Am J Obstet Gynecol; 2023 Dec; 229(6):656.e1-656.e15. PubMed ID: 37595822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
    Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
    Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2.
    Damgaard RK; Jenkins D; Stoler MH; de Koning M; van de Sandt M; Lycke KD; Kahlert J; Gravitt PE; Quint WGV; Steiniche T; Petersen LK; Hammer A
    Am J Obstet Gynecol; 2024 Jun; 230(6):655.e1-655.e10. PubMed ID: 38336125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial comparing cervical dysplasia treatment with cryotherapy vs loop electrosurgical excision procedure in HIV-seropositive women from Johannesburg, South Africa.
    Smith JS; Sanusi B; Swarts A; Faesen M; Levin S; Goeieman B; Ramotshela S; Rakhombe N; Williamson AL; Michelow P; Omar T; Hudgens MG; Firnhaber C
    Am J Obstet Gynecol; 2017 Aug; 217(2):183.e1-183.e11. PubMed ID: 28366730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
    Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
    Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytological surveillance compared with immediate referral for colposcopy in management of women with low grade cervical abnormalities: multicentre randomised controlled trial.
    TOMBOLA Group
    BMJ; 2009 Jul; 339():b2546. PubMed ID: 19638646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years.
    Sykes PH; Simcock BJ; Innes CR; Harker D; Williman JA; Whitehead M; van der Griend RA; Lawton BA; Hibma M; Fitzgerald P; Dudley NM; Petrich S; Eva L; Bergzoll C; Kathuria J; McPherson G; Tristram A; Faherty J; Hardie D; Robertson A; Robertson V; Pather S; Wrede CD; Gastrell F; Fentiman G; John M; White E; Parker C; Sadler L
    Am J Obstet Gynecol; 2022 Feb; 226(2):222.e1-222.e13. PubMed ID: 34534506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopsy and selective recall compared with immediate large loop excision in management of women with low grade abnormal cervical cytology referred for colposcopy: multicentre randomised controlled trial.
    TOMBOLA Group
    BMJ; 2009 Jul; 339():b2548. PubMed ID: 19638647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active expectancy as alternative to treatment for cervical intraepithelial neoplasia grade 2 in women aged 25 to 30 years: ExCIN2-a prospective clinical multicenter cohort study.
    Kylebäck K; Ekeryd-Andalen A; Greppe C; Björkenfeldt Havel C; Zhang C; Strander B
    Am J Obstet Gynecol; 2022 Nov; 227(5):742.e1-742.e11. PubMed ID: 35777432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of guidelines for observational management of cervical intraepithelial neoplasia 2 in young women.
    Dempster-Rivett K; Innes CR; Simcock BJ; Harker D; Williman JA; Van Der Griend RA; Whitehead M; Hibma M; Lawton BA; Fitzgerald P; Dudley NM; Petrich S; Faherty J; Bergzoll C; Eva L; Sadler L; Pather S; Wrede CD; Sykes PH
    Am J Obstet Gynecol; 2020 Sep; 223(3):408.e1-408.e11. PubMed ID: 32109465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study.
    Alder S; Megyessi D; Sundström K; Östensson E; Mints M; Belkić K; Arbyn M; Andersson S
    Am J Obstet Gynecol; 2020 Feb; 222(2):172.e1-172.e12. PubMed ID: 31473226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.
    Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Garcia S; Campo E; Pahisa J; Ordi J
    Am J Obstet Gynecol; 2007 Oct; 197(4):359.e1-6. PubMed ID: 17714678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer: population based cohort study.
    Lycke KD; Kahlert J; Petersen LK; Damgaard RK; Cheung LC; Gravitt PE; Hammer A
    BMJ; 2023 Nov; 383():e075925. PubMed ID: 38030154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California.
    Lonky NM; Xu L; Da Silva DM; Felix JC; Chao C
    Am J Obstet Gynecol; 2021 Dec; 225(6):656.e1-656.e11. PubMed ID: 34273278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cervical intraepithelial neoplasia grade 2 or worse in women aged ≥ 69 referred to colposcopy due to an HPV-positive screening test.
    Booth BB; Tranberg M; Gustafson LW; Christiansen AG; Lapirtis H; Krogh LM; Hjorth IMD; Hammer A
    BMC Cancer; 2023 May; 23(1):405. PubMed ID: 37142959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of cervical intraepithelial neoplasia grade 3 or invasive cancers in ASCUS women with different management: a population-based cohort study.
    Tai YJ; Chen YY; Hsu HC; Chiang CJ; You SL; Chen CA; Cheng WF;
    J Gynecol Oncol; 2018 Jul; 29(4):e55. PubMed ID: 29770625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.
    Elfgren K; Elfström KM; Naucler P; Arnheim-Dahlström L; Dillner J
    Am J Obstet Gynecol; 2017 Mar; 216(3):264.e1-264.e7. PubMed ID: 27825977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.